Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3′,4′-dimethoxy- α-naphthoflavone

Molecular Pharmacology

Volumn 79, Issue 3, 2011, Pages 508-519

  Murray, Iain A ^a   Flaveny, Colin A ^a   Chiaro, Christopher R ^a   Sharma, Arun K ^b   Tanos, Rachel S ^a   Schroeder, Jennifer C ^a   Amin, Shantu G ^b   Bisson, William H ^c,d   Kolluri, Siva K ^c   Perdew, Gary H ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3',4' DIMETHOXY ALPHA NAPHTHOFLAVONE; ALPHA NAPHTHOFLAVONE; AROMATIC HYDROCARBON RECEPTOR; COMPLEMENT COMPONENT C3; MESSENGER RNA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR DOCKING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SAA1 GENE;

ACUTE-PHASE REACTION; BENZOFLAVONES; CELL LINE; COMPLEMENT C3; CYTOKINES; GENE EXPRESSION; HUMANS; INFLAMMATION; LIGANDS; PHOTOAFFINITY LABELS; PROTEIN BINDING; RECEPTORS, ARYL HYDROCARBON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM AMYLOID A PROTEIN;

EID: 79951988195     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.069369     Document Type: Article

References (40)

1. Ashida H, Nishiumi S, and Fukuda I (2008) An update on the dietary ligands of the AhR. Expert Opin Drug Metab Toxicol 4:1429-1447.
2. Beischlag TV, Luis Morales J, Hollingshead BD, and Perdew GH (2008) The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 18:207-250. (Pubitemid 351620286)
3. Bisson WH, Koch DC, O'Donnell EF, Khalil SM, Kerkvliet NI, Tanguay RL, Abagyan R, and Kolluri SK (2009) Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands. J Med Chem 52:5635-5641.
4. Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, Walker JR, Flaveny CA, Perdew GH, Denison MS, et al. (2010) Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329:1345-1348.
5. Cheng N, He R, Tian J, Ye PP, and Ye RD (2008) Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 181:22-26.
6. Cho SY, Park SJ, Kwon MJ, Jeong TS, Bok SH, Choi WY, Jeong WI, Ryu SY, Do SH, Lee CS, et al. (2003) Quercetin suppresses proinflammatory cytokines production through MAP kinases and NF-kappaB pathway in lipopolysaccharide- stimulated macrophage. Mol Cell Biochem 243:153-160.
7. Ciolino HP, Daschner PJ, and Yeh GC (1999) Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem J 340:715-722. (Pubitemid 29312869)
8. Flaveny CA, Murray IA, Chiaro CR, and Perdew GH (2009) Ligand selectivity and gene regulation by the human aryl hydrocarbon receptor in transgenic mice. Mol Pharmacol 75:1412-1420.
9. García-Lafuente A, Guillamón E, Villares A, Rostagno MA, and Martínez JA (2009) Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res 58:537-552.
10. Gasiewicz TA, Kende AS, Rucci G, Whitney B, and Willey JJ (1996) Analysis of structural requirements for Ah receptor antagonist activity: ellipticines, flavones, and related compounds. Biochem Pharmacol 52:1787-1803. (Pubitemid 26407995)
11. Gillner M, Bergman J, Cambillau C, Fernström B, and Gustafsson JA (1985) Interactions of indoles with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Mol Pharmacol 28:357-363. (Pubitemid 16196362)
12. Gu YZ, Hogenesch JB, and Bradfield CA (2000) The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 40:519-561. (Pubitemid 30340692)
13. Henry EC, Kende AS, Rucci G, Totleben MJ, Willey JJ, Dertinger SD, Pollenz RS, Jones JP, and Gasiewicz TA (1999) Flavone antagonists bind competitively with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) to the aryl hydrocarbon receptor but inhibit nuclear uptake and transformation. Mol Pharmacol 55:716-725. (Pubitemid 29165437)
14. Ji H, Gauguier D, Ohmura K, Gonzalez A, Duchatelle V, Danoy P, Garchon HJ, Degott C, Lathrop M, Benoist C, et al. (2001) Genetic influences on the end-stage effector phase of arthritis. J Exp Med 194:321-330. (Pubitemid 32730806)
15. Jux B, Kadow S, and Esser C (2009) Langerhans cell maturation and contact hypersensitivity are impaired in aryl hydrocarbon receptor-null mice. J Immunol 182:6709-6717.
16. Kerkvliet NI, Steppan LB, Vorachek W, Oda S, Farrer D, Wong CP, Pham D, and Mourich DV (2009) Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy 1:539-547.
17. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, and Gustafsson JA (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139:4252-4263. (Pubitemid 28513713)
18. Kushner I and Rzewnicki DL (1994) The acute phase response: general aspects. Baillieres Clin Rheumatol 8:513-530. (Pubitemid 24256889)
19. Long WP, Pray-Grant M, Tsai JC, and Perdew GH (1998) Protein kinase C activity is required for aryl hydrocarbon receptor pathway-mediated signal transduction. Mol Pharmacol 53:691-700. (Pubitemid 28196492)
20. Lu YF, Santostefano M, Cunningham BD, Threadgill MD, and Safe S (1995) Identification of 3′-methoxy-4′-nitroflavone as a pure aryl hydrocarbon (Ah) receptor antagonist and evidence for more than one form of the nuclear Ah receptor in MCF-7 human breast cancer cells. Arch Biochem Biophys 316:470-477.
21. Lu YF, Santostefano M, Cunningham BD, Threadgill MD, and Safe S (1996) Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists. Biochem Pharmacol 51:1077-1087. (Pubitemid 26104628)
22. Murray IA, Flaveny CA, DiNatale BC, Chairo CR, Schroeder JC, Kusnadi A, and Perdew GH (2010a) Antagonism of aryl hydrocarbon receptor signaling by 6,2′,4′- trimethoxyflavone. J Pharmacol Exp Ther 332:135-144.
23. Murray IA, Krishnegowda G, DiNatale BC, Flaveny C, Chiaro C, Lin JM, Sharma AK, Amin S, and Perdew GH (2010b) Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties. Chem Res Toxicol 23:955-966.
24. Murray IA, Morales JL, Flaveny CA, Dinatale BC, Chiaro C, Gowdahalli K, Amin S, and Perdew GH (2010c) Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity. Mol Pharmacol 77:247-254.
25. Pandini A, Soshilov AA, Song Y, Zhao J, Bonati L, and Denison MS (2009) Detection of the TCDD binding-fingerprint within the Ah receptor ligand binding domain by structurally driven mutagenesis and functional analysis. Biochemistry 48:5972-5983.
26. Patel RD, Murray IA, Flaveny CA, Kusnadi A, and Perdew GH (2009) Ah receptor represses acute-phase response gene expression without binding to its cognate response element. Lab Invest 89:695-707.
27. Petrulis JR and Perdew GH (2002) The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem Biol Interact 141:25-40. (Pubitemid 35223203)
28. Poland A, Glover E, Ebetino FH, and Kende AS (1986) Photoaffinity labeling of the Ah receptor. J Biol Chem 261:6352-6365. (Pubitemid 17204144)
29. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, and Weiner HL (2008) Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453:65-71. (Pubitemid 351630328)
30. Savolainen HA and Isomäki HA (1993) Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J Rheumatol 20:1201-1203. (Pubitemid 23278176)
31. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, and Asadullah K (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101:227-232. (Pubitemid 38084232)
32. Sekine H, Mimura J, Oshima M, Okawa H, Kanno J, Igarashi K, Gonzalez FJ, Ikuta T, Kawajiri K, and Fujii-Kuriyama Y (2009) Hypersensitivity of aryl hydrocarbon receptor-deficient mice to lipopolysaccharide-induced septic shock. Mol Cell Biol 29:6391-6400.
33. Singh KP, Casado FL, Opanashuk LA, and Gasiewicz TA (2009) The aryl hydrocarbon receptor has a normal function in the regulation of hematopoietic and other stem/progenitor cell populations. Biochem Pharmacol 77:577-587.
34. Steffan RJ, Matelan E, Ashwell MA, Moore WJ, Solvibile WR, Trybulski E, Chadwick CC, Chippari S, Kenney T, Eckert A, et al. (2004) Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis. J Med Chem 47:6435-6438. (Pubitemid 39657301)
35. Szalai AJ, Hu X, Adams JE, and Barnum SR (2007) Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Mol Immunol 44:3132-3136. (Pubitemid 46610512)
36. Van Dross RT, Hong X, and Pelling JC (2005) Inhibition of TPA-induced cyclooxygenase- 2 (COX-2) expression by apigenin through downregulation of Akt signal transduction in human keratinocytes. Mol Carcinog 44:83-91. (Pubitemid 41397173)
37. Veldhoen M, Hirota K, Christensen J, O'Garra A, and Stockinger B (2009) Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 206:43-49.
38. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, and Stockinger B (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453:106-109. (Pubitemid 351630329)
39. Zhang S, Lei P, Liu X, Li X, Walker K, Kotha L, Rowlands C, and Safe S (2009) The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy. Endocr Relat Cancer 16:835-844.
40. Zhang S, Qin C, and Safe SH (2003) Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ Health Perspect 111:1877-1882. (Pubitemid 37541197)